Malinda Longphre, Ph.D.
Dr. Longphre has more than 20 years of biopharmaceutical industry experience in immunology, inflammation and respiratory therapeutic areas. Prior to joining Connect, Dr. Longphre was Director of Clinical Research at Novartis where she oversaw development of inhaled anti-inflammatory combination products to treat lung disease. Prior to that role, Dr. Longphre was a founding scientist at Aerovance, a spin-out of Bayer Biotechnology’s respiratory biologics portfolio, where her discovery research contributed to the understanding of the importance of IL-4 and IL-13 dysregulation in asthma and atopic dermatitis, and she directed studies of drug candidates that entered Phase 1-3 clinical trials for respiratory disease indications and atopic dermatitis. She was also a discovery scientist at Bristol-Myers Squibb in the department of Immunology, Inflammation and Pulmonary Disease and conducted respiratory inflammation research at the University of California San Francisco. Dr. Longphre is an inventor of nine issued patents for therapeutic entities and targets. She received her Ph.D. in Pulmonary Physiology Environmental Health Sciences at Johns Hopkins University and a M.A. and B.A. in Biology from University of North Carolina Greensboro.